** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7

** Stock on track for its second consecutive session of gains, if trend holds

** The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration (FDA)

** Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren

** NNZ-2591 used for treatment of any traumatic brain injury

** Stock has risen 11.6% so far this year, as of 0054 GMT

(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com))